Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant Oral for Prevention of AF Recurrence
NCT00526136Phase 2Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 2 trial of vernakalant in Atrial fibrillation (AFib), sponsored by ADVANZ PHARMA. Started Mar 2007; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00526136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526136.